|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WFDC3 |
Gene summary for WFDC3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WFDC3 | Gene ID | 140686 |
| Gene name | WAP four-disulfide core domain 3 | |
| Gene Alias | WAP14 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q8IUB2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 140686 | WFDC3 | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.99e-06 | 7.00e-01 | 0.3371 |
| 140686 | WFDC3 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.48e-03 | 5.59e-01 | 0.3385 |
| 140686 | WFDC3 | RNA-P17T-P17T-8 | Human | Lung | IAC | 4.12e-03 | 5.21e-01 | 0.3329 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00525478 | Lung | IAC | regulation of peptidase activity | 80/2061 | 461/18723 | 2.39e-05 | 6.50e-04 | 80 |
| GO:00525488 | Lung | IAC | regulation of endopeptidase activity | 75/2061 | 432/18723 | 4.18e-05 | 1.01e-03 | 75 |
| GO:00458618 | Lung | IAC | negative regulation of proteolysis | 58/2061 | 351/18723 | 1.04e-03 | 1.24e-02 | 58 |
| GO:00109518 | Lung | IAC | negative regulation of endopeptidase activity | 41/2061 | 252/18723 | 6.84e-03 | 4.75e-02 | 41 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WFDC3 | SNV | Missense_Mutation | c.167N>C | p.Cys56Ser | p.C56S | Q8IUB2 | protein_coding | deleterious(0) | possibly_damaging(0.67) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| WFDC3 | SNV | Missense_Mutation | c.681G>T | p.Glu227Asp | p.E227D | Q8IUB2 | protein_coding | tolerated_low_confidence(0.19) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| WFDC3 | SNV | Missense_Mutation | c.66A>G | p.Ile22Met | p.I22M | Q8IUB2 | protein_coding | deleterious(0.01) | benign(0.023) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| WFDC3 | SNV | Missense_Mutation | novel | c.520N>A | p.Leu174Met | p.L174M | Q8IUB2 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| WFDC3 | SNV | Missense_Mutation | novel | c.100N>T | p.Pro34Ser | p.P34S | Q8IUB2 | protein_coding | deleterious(0) | benign(0.117) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WFDC3 | SNV | Missense_Mutation | rs781761019 | c.673N>A | p.Glu225Lys | p.E225K | Q8IUB2 | protein_coding | tolerated_low_confidence(0.09) | benign(0.003) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| WFDC3 | SNV | Missense_Mutation | c.279N>T | p.Glu93Asp | p.E93D | Q8IUB2 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| WFDC3 | SNV | Missense_Mutation | novel | c.263G>T | p.Arg88Met | p.R88M | Q8IUB2 | protein_coding | tolerated(0.09) | benign(0.025) | TCGA-BG-A0VW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WFDC3 | SNV | Missense_Mutation | novel | c.127C>A | p.Leu43Met | p.L43M | Q8IUB2 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WFDC3 | SNV | Missense_Mutation | rs774986590 | c.640N>G | p.Met214Val | p.M214V | Q8IUB2 | protein_coding | tolerated(0.82) | benign(0) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |